OBJECTIVE: As a result of efforts to isolate obesity-promoting genes, the Trp64Arg polymorphism in the b b 3 adrenergic receptor locus, has been studied by many investigators. Results of the studies have varied in statistical signi®cance and magnitude of the association of the polymorphism with body mass index (BMI: kgam 2 ). This has led to controversy about whether this polymorphism is associated with meaningful changes in BMI. To clarify the possible association, we conducted a meta-analysis. DESIGN: Meta-analytic study. MEASUREMENTS: For each genotype of the b b 3 adrenergic receptor (TrpaTrp; TrpaArg; ArgaArg), we extracted the number of subjects, mean and standard deviation of BMI from 23 studies, including 36 different subgroups with a total of 7399 subjects. Other indices and obesity-related variables were not considered. RESULTS: No signi®cant association of the Trp64Arg polymorphism with BMI was found. The weighted mean BMI difference beween TrpaTrp homozygotes and TrpaArg heterozygotes was 0.19 (s.e. 0.11; P 0.07). In addition, the distribution of effect sizes was not signi®cantly heterogeneous (w w 2 38.68; df 35; P 0.31) suggesting that the variation of the effect sizes across the subgroups is not signi®cant. A further weighted regression analysis, utilizing all three genotypes and adjusting for the random subgroup effect, also showed the effect of the polymorphism on BMI is not signi®cant (F 1.72, df (2,54), P 0.19). CONCLUSION: Based on existing data, the Trp64Arg polymorphism does not appear to be signi®cantly associated with BMI. Moreover, we found no evidence for effect heterogeneity, suggesting that the effect of the polymorphism is not moderated by ethnicity or diabetic status.
Introduction
Human obesity is both environmentally and genetically in¯uenced. 1 Development in molecular biology and gene mapping techniques has accelerated the search for the speci®c genes in¯uencing human obesity. 2 The Trp64Arg polymorphism in the b 3 adrenergic receptor locus has drawn recent attention. Some authors suggest that this polymorphism is associated with greater relative body weight (for example, see Refs 3 and 4). However, this purported association has been controversial and results have been apparently contradictory (for example, see Refs 5 and 6) .
Although various studies investigating associations with the Trp64Arg mutation have investigated numerous phenotypes, almost all have body mass index (BMI; kgam 2 ) in common. For this reason and because of our primary interest is obesity, we restricted our attention to BMI in this paper.
There are at least three possible explanations for the aforementioned discrepancies in the literature. First, studies showing signi®cant association might have sampled from populations in which there truly is an association, whereas other studies might have sampled from populations in which there truly is no association. This would imply population heterogeneity with respect to the effect of the b 3 adrenergic receptor locus. However, two other explanations may be equally plausible. Speci®cally, studies showing signi®cant effects could simply represent type I errors. Given the large number of studies conducted, this is plausible. If investigators consider P-values of 0.05 as indicative of statistical signi®cance, then even under the null hypothesis, given more than 20 studies, one would expect a few signi®cant results.
Second, studies showing no signi®cant results could represent type II errors. Given the sample sizes used in some studies and a potentially modest effect, type II errors might be expected. Meta-analysis is a powerful tool for quantitatively, objectively and comprehensively assessing the relative merit of these three competing explanations. Pooling data from many studies into a single analysis reduces the problems of multiple hypothesis testing and the plausibility of type I errors as only a single departure from the null is considered. This pooling also yields excellent statistical power and therefore reduces the type II error probability. Finally, meta-analysis can rigorously test effect heterogeneity, allowing more objective statements about effect of the polymorphism in different populations.
Methods

Data retrieval procedure
We established the following criteria: 1) The study measured both BMI and genotype (TrpaTrp, TrpaArg, ArgaArg) of the b 3 adrenergic receptor locus; 2) The study analysed human subjects and 3) The study was published (excluding abstract form) or became available to us no later than 31 May 1997.
With these criteria, we searched electronic databases such as Medline and recent issues of`key' journals, such as: New England Journal of Medicine, Lancet, Science, Nature, International Journal of Obesity, Diabetes, Diabetes Care, Diabetologia, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Investigation and Obesity Research. Finally, we made contacts within the`invisible college' for updated or unpublished information.
Isolation of data
A total of 27 papers were identi®ed that met the inclusion criteria (see Table 1 ). However, several studies did not adequately report data in a way that allowed inclusion in this meta-analysis. Speci®cally, we needed to know, within each speci®c genotype, the mean BMI, the standard deviation of BMI and the number of subjects. For some articles, even though these statistics were not reported, they could be calculated from other information available. For the remaining articles where these statistics were not directly reported or calculable from additional information, we contacted the corresponding authors which increased our ability to include the majority of the studies.
In many cases, data were reported based on certain subgroups (for example, males vs females, diabetic vs non-diabetic subjects, young vs old subjects, etc.). Accordingly, effect sizes were calculated separately within each subgroup prior to pooling. This strati®ca-tion decreases the potential for confounding and allows a better assessment for possible heterogeneity across the subgroups. One type of strati®cation that we did not maintain was strati®cation by BMI. Under the alternative hypothesis that there is an association between the polymorphism in question and BMI, stratifying by BMI (for example, analysing the association separately in the obese and non-obese subjects within the sample) will almost certainly attenuate the statistical signi®cance of the association. 30 Therefore, whenever studies reported such information by obesity status or BMI category, the data were disagregated. Means of the total sample in such disagregated data sets, were calculated as the weighted mean of the two (or more) subsamples. Variances of the total sample were calculated as the weighted average of the two (or more) subsample variances plus the weighted mean squares among groups.
The ®nal 43 identi®ed subgroups from 27 studies are listed in Table 1 . A total of 36 distinct subgroups (from 23 studies; subgroups with ID numbers 1±36 in Table 1 ) was attained for the main meta-analyses. For sensitivity analyses, we added seven more subgroups from four other studies, where obtainable information was incomplete (subgroups with ID numbers 37±43 in Table 1 ).
Statistical analyses
To estimate the overall mean BMI difference between individuals heterozygous (TrpaArg) for and homozygous (TrpaTrp) without the Trp64Arg polymorphism, we extracted the mean and standard deviation of BMI from each subgroup and each genotype. Across all subgroups, the overall difference was estimated via a weighted pooled mean difference D, that is,
where n the total number of subgroups, d i mean i (BMIjTrp/Arg) 7 mean i (BMIjTrp/Trp), and w i 1aVar(d i ) for the i-th subgroup. This weighting by the reciprocal of their variances is known to produce minimum variance of the pooled weighted mean difference when each mean difference is independent. 31 The standard error of D can be estimated as follows:
Therefore, the test statistic Z DaSED is asymptotically normally distributed with mean zero and variance 1, which allows one to test the signi®cance of the weighted pooled mean difference. Heterogeneity of the mean BMI differences across the subgroups can be tested by a w 2 test statistic, Q, with degree of freedom
where n is the total number of the subgroups. Finally, a test of the effects of the Trp64Arg polymorphism on BMI can be performed using all three genotypes by the following weighted quadratic meta-regression analysis 32 with consideration of subgroup effect as follows:
where G ij is the number of Trp64Arg alleles the subjects of the j-th genotype in the i-th subgroup have, d is the random subgroup effect, and e is the Meta-analysis of Trp64 Arg polymorphism DB Allison et al Meta-analysis of Trp64 Arg polymorphism DB Allison et al error term. More speci®cally, G ij is equal to zero for an individual with the genotype of TrpaTrp, 1 with TrpaArg, and 2 with ArgaArg. The weights were taken as the inverse of the variance of the mean BMI in the j-th genotype of the i-th subgroup. The inclusion of the random study effect would adjust the polymorphism effect on BMI for variation due to study subject characteristics such as ethnicity. 33 
Results
Main meta-analysis
The pooled sample size is 7399 (5396 TrpaTrp homozygotes, 1815 TrpaArg heterozygotes and 188 ArgaArg homozygotes). From this pooled sample, the weighted mean BMI difference between TrpaArg heterozygotes and TrpaTrp heterozygotes was not signi®cant; D AE SED 0X192 AE 0X107, Z 1X79Y P 0X07. Therefore, the Trp64Arg polymorphism was not signi®cantly associated with BMI. Figure 1 depicts the mean and 95% con®dence intervals of each BMI difference across the 36 subgroups and that of the weighted BMI difference. The numbers on the abscissa of Figure 1 represents the subgroup identi®-cation numbers in Table 1 . Heterogeneity in the distribution of the mean differences of BMI across the subgroups of the studies included was not signi®cant (Q 38.68, df 35, P 0.31). Thus, variation in the association between Trp64Arg alleles and BMI across studies is consistent with random sampling variability.
Finally, no signi®cant effects of the Trp64Arg polymorphism on BMI were observed in the regression analysis: no signi®cant linear effect b 1 0X195Y P 0X53; no signi®cant quadratic effect b 2 0X012Y P 0X95; no signi®cant joint effect (F 1.72, df (2,54), P 0.19). The random effect of the subgroups was seen to be signi®cant P`0X001, which implies that the adjusted mean BMI levels analysed in the subgroups differ. However, it does not nullify the non-signi®cant ®nding of primary interest, that is, individuals with and without the polymorphism across the subgroups do not differ in BMI on average.
Exploratory analyses
It has been speculated that the association of the Trp64Arg polymorphism with BMI (as well as the effect of the polymorphism on BMI) may be heterogeneous among ethnic groups or over the diabetic status of the individuals. To test this hypothesis, we conducted additional exploratory analyses including: (1) pair-wise tests of equality of associations between groups, and (2) analyses of covariance (ANCOVA) adjusting for ethnicity and diabetic status, respectively, and testing interactions between ethnicity and diabetic status with genotype of the polymorphism. Ethnicity was categorized as Japanese, Caucasian and other', because subjective inspection of the data suggested that the association of the polymorphism with BMI might be greater in Japanese than Caucasian samples.
As seen in Table 2 , the weighted mean BMI difference (between TrpaTrp homozygotes and Figure 1 Mean differences of body mass index (BMI) and their 95% con®dence intervals (CI) across the subgroups of the studies included with a weighted pooled estimate (P 0.07); the subgroup ID numbers are listed in Table 1 .
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TrpaArg heterozygotes) within each ethnic group, was not signi®cant. Similarly, there were no differences between groups as determined by the pair-wise tests. In terms of diabetic status, the only statistically signi®cant weighted mean BMI difference emerged within the identi®ed non-diabetic individuals (P 0.042), while the difference was not signi®cant for the other two groups. However, in terms of the pair-wise tests of the equality of association between groups with different diabetic status, there were no signi®cant differences. Moreover, the marginally signi®cant P-value of 0.042 for the non-diabetic group should be interpreted in the light of the post-hoc nature of the signi®cance test and the number of exploratory anlayses conducted. Were an ordinary Bonferroni test applied, this result would not be signi®cant.
Regarding the effect of the polymorphism on BMI by ethnicity and diabetic status, when all three genotypes were used, Table 3 shows that there are no signi®cant effects of the polymorphism on BMI. Furthermore, as indicated by the non-signi®cant interaction terms, this null effect of the polymorphism is consistent across both ethnicity and diabetic status. There were signi®cant main effects of ethnicity and diabetic status on BMI. This again implies that the adjusted mean BMI levels differ between ethnic groups and by diabetic status. However, it also implies that ethnicity and diabetic status do not moderate the (non)effect of b 3 on BMI.
Sensitivity analysis
For a sensitivity analysis, we added seven more subgroups from four studies (subgroup ID 37±43 in Table 1 ), which resulted in a total of 8242 subjects (6010 TrpaTrp homozygotes, 2032 TrpaArg heterozygotes, 200 ArgaArg heterozygotes). The mean, s.d. and the number of subjects within each genotype of these subgroups, could not be obtained and were therefore estimated indirectly (see footnotes to Table  1 ). Therefore, these seven subgroups are not necessarily comparable with those used in the main metaanalysis for reasons described in the footnotes of Table 1 .
In the sensitivity analysis, the estimated overall weighted mean difference and its standard error were 0.176 and 0.100, respectively (P 0.080). The w 2 test statistic, Q, with df 42 was 51.29 (P 0.15). These results are consistent with those of the main meta-analysis. From the weighted regression analysis, neither the linear nor the quadratic effect of the 5, 6, 7, 8, 11, 12, 13, 21, 22, 23, 27, 30, 31, 32) ; O: Others (ID; 1, 19, 20, 33, 34, 35, 36) . b Diabetic Status; D: diabetics (ID; 3, 8, 11, 12, 21) ; N: non-diabetics (ID; 2, 5, 7, 13, 14, 19, 20, 22, 23, 26, 30, 31) ; CaU: combinedaUnknown (ID; 1, 4, 6, 9, 10, 15, 16, 17, 18, 24, 25, 27, 28, 29, 32, 33, 34, 35, 36) .
number of`Arg' alleles was observed to be signi®cant ( b 1 À0X042Y P 0X88Y b 2 0X223Y P 0X21. Although they are jointly signi®cant (F 4.42, df (2,63), P 0.016), the increment of the predicted mean BMI with the number of`Arg' allele is trivial± increment of 0.81 BMI from zero to two`Arg' alleles.
Discussion
The meta-analysis revealed no signi®cant association between the Trp64Arg polymorphism in the b 3 adrenergic receptor locus and BMI. This lack of association was found despite enormous statistical power. Moreover, there is no statistically signi®cant evidence for heterogeneity of the effect across the studies. Thus, while it is plausible that this polymorphism has an important effect on BMI in some populations but not in others, currently available data do not support this conjecture. That is, the null ®nding cannot be dismissed on the basis of interpopulation heterogeneity.
It is noteworthy that the estimated effect of the Trp64Arg polymorphism on BMI remains small even if one assumes that these were a`true' effect that fell at the upper end of the computed 95% con®dence interval. Among the available sample of studies, this corresponds to an upper bound effect size of D BMI 0.40. To put this in perspective, consider a hypothetical individual 67 inches tall. For this individual, having the polymorphism would only confer an additional 1.16 kg. Sensitivity analysis suggested that, were we able to include data from four additional studies, the results from the regression analysis might be signi®cant. However, since the preparation of the present meta-analysis, there have been at least two additional publications 34, 35 showing non-signi®cant associations between the Trp64Arg polymorphism and BMI. Moreover, results from one large study 36 with more than 1000 subjects, which was not included in this meta-analysis due to incomplete information, also showed non-signi®cant associations. It therefore seems unlikely that our conclusions would change were`accurate' measurements from the four additional studies used in the sensitivity analysis made available.
When interpreting these data, one must consider the potential for publication bias, or the tendency of signi®cant ®ndings to have a greater probability of being published. This has been documented in the obesity treatment literature 37 and, at present, generally tends to yield overestimates of effects. In other words, many investigators regularly publish the statistically signi®cant ®ndings they obtain, but are less likely to publish ®ndings that are not statistically signi®cant. If many studies are undertaken on a particular topic and only the statistically signi®cant studies are published, this will obviously lead to biased estimates of the effect studied. To the extent that such a situation existed in the current literature, this further argues for the lack of effect of the Trp64Arg polymorphism on BMI. However, we note that many of the published ®ndings did in fact report non-signi®cant results or small effects. This suggests that the effects of publication bias were probably minimal in the literature reviewed. This is supported by a funnel plot 37, 38 in Figure 2 , in which the average mean BMI difference does not appear to 39 that is, tests with lower power compared to alternative tests of the same hypothesis. For future studies, we suggest that the genotype may be the best choice as the independent variable and the phenotype, expressed in a continuous metric regardless of selection procedure, the best choice for the dependent variable, and a simple 2 df one-way analysis of variance (ANOVA) a reasonable analytic procedure. Relevant covariates can also be modeled and analysed by analysis of covariance (ANCOVA). If concerns about parametric assumptions argue against these tests, non-parametric analogues might be considered. Stratifying the analysis by the levels of the phenotype is probably not useful. Finally, consistent reporting of the mean, standard deviation and sample size within each genotypically de®ned group is recommended to facilitate future meta-analytic work and cross study comparisons.
This analysis only examined the association between the Trp64Arg polymorphism and BMI. It makes no statements about the effect or lack 40 thereof, between this polymorphism and other obesity-or diabetes-related variables. Signi®cant associations with such phenotypes might exist. Moreover, in terms of physiological pathway, early studies of the functional characteristics of the Trp64Arg-variant b 3 adrenergic receptor (b3AR) are inconclusive. Studies of ligand binding, adenyl cyclase activation and desensitization have failed to show any differences between the normal b3AR and the Trp64Arg variant. 41 In vitro studies of omental adipose tissue have also shown no differences in rates of lipolysis between those homozygous for the normal b3AR and those heterozygous for the Trp64Arg variant.
14 Recently, Pie Âtri-Rouxel et al 42 analysed the biochemical effect of the genes encoding the wild type of the Trp64Arg polymorphism in two cell lines Ð Chinese hamster ovary cells and human embroyonic kidney cells. In both cell lines the stimulation of the Trp64Arg adrenergic receptor variant, resulted in a lower maximal level of adenylyl cyclase relative to the wild type polymorphism. Pie Âtri-Rouxel et al 42 argued that this biochemical dysfunction could be important in the pathophysiology of obesity.
Despite these caveats, this meta-analysis provides clear evidence of a lack of association between BMI variation and the Trp64Arg polymorphism of the b 3 adrenergic receptor gene. We believe that the metaanalytic technique illustrated here, may also be useful for the pooling of other association studies within the obesity arena.
